Drug
[18F]-αvβ6-BP
[18F]-αvβ6-BP is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
2
67%
Ph phase_1
1
33%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 12 (66.7%)
Phase 11 (33.3%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
completedearly_phase_1
PET/CT Imaging in COVID-19 Patients
NCT04376593
recruitingphase_1
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
NCT05452005
active_not_recruitingearly_phase_1
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
NCT03164486
Clinical Trials (3)
Showing 3 of 3 trials
NCT04376593Early Phase 1
PET/CT Imaging in COVID-19 Patients
NCT05452005Phase 1
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
NCT03164486Early Phase 1
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3